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ABSTRACT	  
Prelamin	  A,	   a	  CaaX-­‐protein	   is	   a	   key	   structural	   protein	   of	   the	   inner	  nuclear	   lamina,	   a	  meshwork	   lining	   the	   inner	  nuclear	   envelope.	   Farnesylated	   prelamin	   A	   is	   cleaved	   just	   upstream	   of	   the	   farnesylcysteine	   residue	   to	   produce	  mature	  lamin	  A.	  We	  generated	  Zmpste24	  knockout	  mice	  and	  documented	  a	  striking	  accumulation	  of	  farnesylated	  and	  methylated	   prelamin	   A	   in	   cells.	   Zmpste24	   knockout	   cells	   exhibit	   premature	   senescence	   and	  misshapen	   cell	  nuclei.	  Zmpste24	  knockout	  mice	  show	  slow	  growth,	  hair	  loss,	  micrognathia,	  bone	  fractures,	  muscle	  weakness,	  and	  premature	  death.	  These	  phenotypes	  are	  similar	  to	  those	  in	  HGPS.	  HGPS	  is	  caused	  by	  a	  LMNA	  point	  mutation	  that	  leads	  to	  the	  deletion	  of	  50	  amino	  acids	  in	  the	  carboxyl	  terminus	  of	  prelamin	  A	  (eliminating	  the	  ZMPSTE24	  cleavage	  site	  and	  preventing	  formation	  of	  mature	  lamin	  A).	  Consequently,	  a	  mutant	  farnesylated	  and	  methylated	  prelamin	  A	  accumulates	  at	  the	  nuclear	  rim	  in	  HGPS	  cells,	  interfering	  with	  the	  nuclear	  lamina	  and	  causing	  misshapen	  cell	  nuclei.	  	  
Specific	  Aim	  and	  Results	  of	  Paper	  1:	  To	  define	  the	  importance	  of	  ICMT	  in	  the	  pathogenesis	  and	  treatment	  of	  
progeria.	   In	   this	   project	   we	   bred	   Zmpste24	   knockout	   mice	   with	   mice	   harboring	   a	   hypomorphic	   (reduced	  expression)	  allele	  of	  Icmt.	  We	  found	  that	  these	  mice	  where	  protected	  from	  most	  aspects	  of	  progeroid	  disease.	  They	  had	   an	   increased	   survival,	   lack	   of	   osteoporosis,	   and	   increased	   strength.	   Icmt	   inhibition	   in	   cells	   derived	   from	  Zmpste24	  KO	  mice	  and	  cells	   from	  human	  progeria	  patients	  also	  showed	  increased	  proliferative	  and	  somatrophic	  activity,	  without	  affecting	  the	  frequency	  of	  nuclear	  shape	  abnormalities	  which	  is	  one	  of	  the	  hallmark	  phenotypes	  of	  progeria.	  
Specific	  Aim	  and	  Results	  of	  Paper	  2:	  To	  test	  the	  hypothesis	  that	  prelamin	  A	  is	  a	  tumor	  suppressor.	  We	  bred	  
Zmpste24	  knockout	  mice	  with	  mice	  expressing	  a	  Cre-­‐inducible	  endogenous	  oncogenic	  K-­‐RAS	  and	  B-­‐Raf	  alleles	  (K-­‐RASLSL/+	  and	  B-­‐RafCA).	  Groups	  of	  mice	  where	  then	  allowed	  to	  inhale	  a	  Cre-­‐	  adenovirus	  to	  activate	  the	  expression	  of	   oncogenic	   K-­‐RASG12D/+	   and	   B-­‐RafV600E	   in	   lung	   cells	   (these	   mice	   normally	   develop	   lung	   adenomas	   to	  adenocarcinoma	   without	   metastases).	   10	   and	   8	   weeks	   post	   inhalation	   mice	   were	   euthanized	   and	   lungs	   where	  prepared	  for	  routine	  histology.	  Surprisingly,	  Zmpste24-­‐deficiency	  had	  no	  impact	  on	  the	  development	  K-­‐RASG12D/+	  and	  B-­‐RafV600E	  driven	  tumor	  except	  for	  a	  reduction	  in	  grade.	  Furthermore,	  fibroblasts	  derived	  from	  the	  same	  mice	  could	  be	  readily	  transformed	  and	  proliferated	  at	  the	  same	  rate	  as	  Zmpste24	  competent	  cells.	  Finally,	  K-­‐RASG12D/+,	  B-­‐RafV600E	  Zmpste24-­‐fibroblasts	  had	  significantly	  reduced	  basement	  membrane	  invasiveness.	  
Keywords:	  progeria,	  cancer,	  aging	  ISBN:	  978-­‐91-­‐628-­‐9014-­‐8	  
